| Autor: |
Yassir M, Almatrafi, Mohammed A, Babakkor, Muhammed, Irfan, Ebaa T, Samkari, Waleed M, Alzahrani, Doaa K, Mohorjy, Sarmad, Zahoor, Muhammad T, Farooq, Hafiz M, Sajid Jehangir |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Neurosciences. 27:65-70 |
| ISSN: |
1658-3183 |
| Popis: |
To assess the efficacy and safety of rituximab for multiple sclerosis (MS) treatment in terms of reduction in clinical relapses, magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS) score and adverse events.This is a retrospective cross-sectional study conducted at King Abdullah Medical City, from January 2017 to August 2021, involving patients with MS given rituximab, with 1-year follow-up. Clinical parameters were noted pre- and post-treatment to determine efficacy; adverse events were noted to analyze safety. A paired samples t-test was used to compare responses pre- and post-treatment. AAmong 31 patients, 6 (19.4%) had progressive MS, and 25 (80.6%) had relapsing-remitting MS (mean disease duration=8.12±5.65 years). The annual relapse rate reduced from 1.67±0.97 to 0.06±0.25 (Rituximab is an efficient drug in reducing the annual relapse rate and MRI activity of patients with MS, with few tolerable side effects not leading to drug discontinuation or any lethal outcome. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
